237 related articles for article (PubMed ID: 33991528)
1. Follicular cells in pituitary neuroendocrine tumors.
Delfin L; Mete O; Asa SL
Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
[TBL] [Abstract][Full Text] [Related]
2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
3. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
4. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin profiles in pituitary neuroendocrine tumors.
Asa SL; Mete O
Hum Pathol; 2021 Jan; 107():87-95. PubMed ID: 33098891
[TBL] [Abstract][Full Text] [Related]
6. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
7. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
8. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.
Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S
Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666
[TBL] [Abstract][Full Text] [Related]
10. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O; Cintosun A; Pressman I; Asa SL
Mod Pathol; 2018 Jun; 31(6):900-909. PubMed ID: 29434339
[TBL] [Abstract][Full Text] [Related]
12. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
14. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
15. Intratumoural spatial distribution of S100B + folliculostellate cells is associated with proliferation and expression of FSH and ERα in gonadotroph tumours.
Ilie MD; Vasiljevic A; Chanal M; Gadot N; Chinezu L; Jouanneau E; Hennino A; Raverot G; Bertolino P
Acta Neuropathol Commun; 2022 Feb; 10(1):18. PubMed ID: 35139928
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
17. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
[TBL] [Abstract][Full Text] [Related]
18. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
19. [Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study].
Duan ZJ; Feng J; Zhao HQ; Wang HD; Gui QP; Zhang XF; Ma Z; Hu ZJ; Xiang L; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1017-1024. PubMed ID: 37805393
[No Abstract] [Full Text] [Related]
20. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
